Andrew von Eschenbach news from FiercePharma
News
Stupak: FDA needs subpoena power
Rep. Bart Stupak might be a severe FDA critic, but he's also shaping up to be the agency's dearest friend. Chief of the House Energy and Commerce committee's oversight-and-investigations group,
Read more...The FDA's surprising plea for cash
Finally, FDA chief Andrew von Eschenbach is crying uncle. After weeks of pressure from Congress to request more money for the agency--and weeks of Read more...
FDA aims to hire 1,300 by October
In answer to its critics, FDA is mounting a major hiring push to expand its drug safety operations. By October, it hopes to add 1,300 to its payroll--600 new positions and 700 vacancies that have Read more...
FDA: Drugmakers responsible for safety
Congress may be all fired up about funding more foreign inspections by the FDA, but the agency itself? Not so much. In Read more...
FDA Commish chided over import safety
FDA Commissioner Andy von Eschenbach found himself in the hot seat again at a Congressional Read more...
FDA chief suspects heparin 'fraud'
The FDA believes Baxter International's recalled heparin was tainted "by virtue of economic fraud," Commissioner Andrew von Eschenbach told a Senate panel yesterday. That heparin has been Read more...
ALSO NOTED: Senate panel offers more FDA funding; Japan OKs Roche's Actemra, Abbott's Humira
> A bipartisan Senate panel agreed that the FDA is "seriously underfunded" and asked Commissioner Andrew von Eschenbach for an estimate of how much more money the agency could use wisely in the Read more...
Planning for the FDA's overhaul
Just about everybody agrees that the FDA needs a safety overhaul--including Commissioner Andrew von Eschenbach, who Read more...
ALSO NOTED: Ranbaxy to produce generic Pfizer drug; Keryx triggers big shakeup;
> The weak dollar and the loss of a key patent depressed Boehringer Ingelheim's full-year results; sales grew 3.6 percent, fed mostly by the 30 percent jump in its lung treatment Spiriva. Read more...
Get more Andrew von Eschenbach coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight